Report from the sixth international workshop on Waldenström's macroglobulinemia

Clinical Lymphoma, Myeloma and Leukemia

Volumn 11, Issue 1, 2011, Pages 69-73

  Treon, Steven P ^a   Merlini, Giampaolo ^b   Morra, Enrica ^c   Patterson, Christopher J ^a   Stone, Marvin J ^d  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PAVIA   (Italy)

^c OSPEDALE NIGUARDA CA GRANDA   (Italy)

^d BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; ALKYLATING AGENT; ANTINEOPLASTIC AGENT; BENDAMUSTINE; BORTEZOMIB; CARFILZOMIB; CHLORAMBUCIL; CLADRIBINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; EVEROLIMUS; FLUDARABINE; MLN 4924; NUCLEOSIDE ANALOG; PANOBINOSTAT; PROTEIN INHIBITOR; RITUXIMAB; UNCLASSIFIED DRUG;

AMYLOIDOSIS; BING NEEL SYNDROME; CENTRAL NERVOUS SYSTEM DISEASE; CONFERENCE PAPER; CONSENSUS DEVELOPMENT; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DRUG EFFICACY; DRUG RESPONSE; FAMILIAL DISEASE; GENE DOSAGE; HUMAN; HUMORAL IMMUNITY; IMMUNE DEFICIENCY; MARGINAL ZONE LYMPHOMA; MONOCLONAL IMMUNOGLOBULINEMIA; MYELODYSPLASTIC SYNDROME; NEUROPATHY; NONHODGKIN LYMPHOMA; PERIPHERAL NEUROPATHY; PROGNOSIS; SINGLE NUCLEOTIDE POLYMORPHISM; WALDENSTROEM MACROGLOBULINEMIA;

EID: 79953691832     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.3816/CLML.2011.n.010     Document Type: Conference Paper

References (52)

1. Waldenstrom J. Incipient myelomatosis or essential hyperglobulinemia with fibrinogenopenia-A new syndrome? Acta Med Scand 1944; 117:217-47.
2. Owen RG, Treon SP, Al-Katib A, et al. Clinicopathological definition of Waldenström's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenström's macroglobulinemia. Semin Oncol 2003; 30:110-15. (Pubitemid 36506291)
3. Kyle RA, Treon SP, Alexanian R, et al. Prognostic markers and criteria to initiate therapy in Waldenstrom's Macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol 2003; 30:116-20. (Pubitemid 36506292)
4. Gertz M, Anagnostopoulos A, Anderson KC, et al. Treatment Recommendations in Waldenstrom's Macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol 2003; 30:121-6. (Pubitemid 36506293)
5. Weber D, Treon SP, Emmanouilides C, et al. Uniform response criteria in Waldenstrom's Macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol 2003; 30:127-131. (Pubitemid 36506294)
6. Harris NL. Lymphoplasmacytic lymphoma: Pathological features. Proceedings of the 6th International Workshop on Waldenstrom's Macroglobulinemia, Venice, Italy 2010; p 27.
7. Mikhael J. Differentiating IgM multiple myeloma from Waldenstrom's Macroglobulinemia. Proceedings of the 6th International Workshop on Waldenstrom's Macroglobulinemia, Venice, Italy 2010; p 33.
8. Arcaini L. Distinguishing Waldenstrom's Macroglobulinemia and Splenic Marginal Zone Lymphoma (SMZL).Proceedings of the 6th International Workshop on Waldenstrom's Macroglobulinemia, Venice, Italy 2010; p 31.
9. Kyrtsonis MC, Levidou G, Pangalis GA, et al. CD138 possibly distingusihes Waldenstrom's Macroglobulinemia from Splenic Marginal Zone Lymphoma. Proceedings of the 6th International Workshop on Waldenstrom's Macroglobulinemia, Venice, Italy 2010; p 32.
10. Morice WG. Novel immunophenotypic features of Waldenstrom's Macroglobulinemia. Proceedings of the 6th International Workshop on Waldenstrom's Macroglobulinemia, Venice, Italy 2010; p 29.
11. Kyle RA. IgM Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Waldenstrom's Macroglobulinemia. Proceedings of the 6th International Workshop on Waldenstrom's Macroglobulinemia, Venice, Italy 2010; p 35.
12. Morra E. Factors predicting evolution of asymptomatic IgM MGUS and IgM-related disorders. Proceedings of the 6th International Workshop on Waldenstrom's Macroglobulinemia, Venice, Italy 2010; p 36.
13. Landgren O. Risk factors for lymphoplasmacytic lymphoma/Waldenstrom Macroglobulinemia. Proceedings of the 6th International Workshop on Waldenstrom's Macroglobulinemia, Venice, Italy 2010; p 40.
14. McMaster M, Pfeiffer RM, Koshiol J. Evidence for the contribution of environmental exposures to the etiology of familial Waldenstrom's Macroglobulinemia. Proceedings of the 6th International Workshop on Waldenstrom's Macroglobulinemia, Venice, Italy 2010; p 41.
15. Hunter Z, Hanzis C, Ioakimidis L, et al. Characteristics of Familial Waldenstrom's Macroglobulinemia. Proceedings of the 6th International Workshop on Waldenstrom's Macroglobulinemia, Venice, Italy 2010; p 42.
16. Braggio E, Fonseca R. The analysis of copy number abnormalities profile in Waldenstrom's Macroglobulinemia and related low-grade B-cell entities by array-based comparative genomic hybridization (aCGH) identifies disease-specific and common abnormalities across entities. Proceedings of the 6th International Workshop on Waldenstrom's Macroglobulinemia, Venice, Italy 2010; p 44.
17. Poulain S, Roumeir C, Aijjou R, et al. Genome wide SNP array analysis in Waldenstrom's Macroglobulinemia. Proceedings of the 6th International Workshop on Waldenstrom's Macroglobulinemia, Venice, Italy 2010; p 45.
18. Zhou Y, Xia L, Xu L, et al. Involvement of Ets factor Spi-B and Id2 in Waldenstrom's Macroglobulinemia. Proceedings of the 6th International Workshop on Waldenstrom's Macroglobulinemia, Venice, Italy 2010; p 50.
19. Ansell S, Grote D, Elsawa SF, et al. Inhibition of the Jak/Stat pathway in Waldenstrom's Macroglobulinemia. Proceedings of the 6th International Workshop on Waldenstrom's Macroglobulinemia, Venice, Italy 2010; p 58.
20. Joshua D, Brown R. Clonal expansion of CTLs in Waldenstrom's Macroglobulinemia. Proceedings of the 6th International Workshop on Waldenstrom's Macroglobulinemia, Venice, Italy 2010; p 52.
21. Gorochov G, Parizot C, Toma A, et al. Impaired regulatory T cell function in Waldenstrom's Macroglobulinemia. Proceedings of the 6th International Workshop on Waldenstrom's Macroglobulinemia, Venice, Italy 2010; p 53.
22. Prabhala R, Pelluru D, Fulciniti et al. The role of TH17 pathway in Waldenstrom's Macroglobulinemia. Proceedings of the 6th International Workshop on Waldenstrom's Macroglobulinemia, Venice, Italy 2010; p 54.
23. Rawstron AC, Dalal S, Cullen F, et al. Progressive humoral immune suppression in indolent B-cell malignancies. Proceedings of the 6th International Workshop on Waldenstrom's Macroglobulinemia, Venice, Italy 2010; p 57.
24. Owen RG, Johnson SA, Lejeune J, et al. International Phase III study of chlorambucil versus fludarabine as initial therapy for Waldenstrom's Macroglobulinemia and related disorders: Results in 414 patients. Proceedings of the 6th International Workshop on Waldenstrom's Macroglobulinemia, Venice, Italy 2010; p 73.
25. Rummel MJ, Niederle N, von Grunhagen U, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first line treatment in patients with indolent lymphomas and Waldenstrom's Macroglobulinemia. Proceedings of the 6th International Workshop on Waldenstrom's Macroglobulinemia, Venice, Italy 2010; p 76.
26. Treon SP. Treatment advances in Waldenstrom's Macroglobulinemia. Proceedings of the 6th International Workshop on Waldenstrom's Macroglobulinemia, Venice, Italy 2010; p 78.
27. Ghobrial I.M. Primary therapy of Waldenstroms Macroglobulinemia with bortezomib and rituximab .Proceedings of the 6th International Workshop on Waldenstrom's Macroglobulinemia Venice Italy 2010 84
28. Tedeschi A, Benevolo G, Varettoni M, et al. Multicenter study of fludarabine, cyclophosphamide and rituximab in untreated and previously treated Waldenstrom Macroglobulinemia. Proceedings of the 6th International Workshop on Waldenstrom's Macroglobulinemia, Venice, Italy 2010; p 74.
29. Lazlo D, Andreola G, Rigaci L, et al. Rituximab and subcutaneous 2-chloro-2'-deoxyadenosine (2CDA) combination treatment for patients with Waldenstrom's Macroglobulinemia: Clinical and biological reults of a phase II multicenter study. Proceedings of the 6th International Workshop on Waldenstrom's Macroglobulinemia, Venice, Italy 2010; p 79.
30. Leleu XP, Manning R, Soumerai JD, et al. Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenström macroglobulinemia treated with nucleoside analogs. J Clin Oncol 2009; 27:250-5.
31. Ghobrial I, Poon T, Rourke M, et al. Phase II trial of single agent panobinostat (LBH589) in relapsed or relapsed/refractory Waldenstrom Macroglobulinemia. Proceedings of the 6th International Workshop on Waldenstrom's Macroglobulinemia, Venice, Italy 2010; p 82.
32. Ioakimidis L, Hanzis C, Manning RJ, et al. Maintenance rituximab is associated with improved clinical outcome in rituximab nal̈ve patients with Waldenstrom's Macroglobulinemia who respond to a rituximab containing regimen. Proceedings of the 6th International Workshop on Waldenstrom's Macroglobulinemia, Venice, Italy 2010; p 81.
33. Treon SP, Yang G, Hanzis C, et al. CR/VGPR following rituximab-based therapy is an important determinant to progression free survival, and is impacted by polymorphisms in the Fc?RIIIA receptor in Waldenstrom's Macroglobulinemia. Proceedings of the 6th International Workshop on Waldenstrom's Macroglobulinemia, Venice, Italy 2010; p 69.
34. Kristinsson S. Patterns of survival in lymphoplasmacytic lymphoma/Waldenstrom Macroglobulinemia: A population based study of 1,555 patients diagnosed in Sweden from 1980-2005.Proceedings of the 6th International Workshop on Waldenstrom's Macroglobulinemia, Venice, Italy 2010; p 67.
35. Yang G, Hanzis C, Hunter ZR, et al. The anti-CD20 monoclonal antibody GA101 displays more robust anti-tumor activity versus rituximab or ofatumumab in Waldenstrom's Macroglobulinemia. Proceedings of the 6th International Workshop on Waldenstrom's Macroglobulinemia, Venice, Italy 2010; p 71.
36. Mitsiades C. Novel proteasome inhibitors. Proceedings of the 6th International Workshop on Waldenstrom's Macroglobulinemia, Venice, Italy 2010; p 70.
37. Sacco A, Roccaro A, Azab AK, et al. NVP-BEZ235 exerts anti-tumor activity in Waldenstrom's Macroglobulinemia. Proceedings of the 6th International Workshop on Waldenstrom's Macroglobulinemia, Venice, Italy 2010; p 104.
38. Sheehy P, Hanzis C, Ioakimidis L, et al. Clinical characteristics and treatment outcome of diseaase related peripheral neuropathy in Waldenstrom's Macroglobulinemia. Proceedings of the 6th International Workshop on Waldenstrom's Macroglobulinemia, Venice, Italy 2010; p 123.
39. Nobile-Orazio E. Antigenic determinants in IgM related neuropathies. Proceedings of the 6th International Workshop on Waldenstrom's Macroglobulinemia, Venice, Italy 2010; p 119.
40. Steck A. Rituximab for anti-MAG neuropathy. Proceedings of the 6th International Workshop on Waldenstrom's Macroglobulinemia, Venice, Italy 2010; p 121.
41. Karlin L, Arnulf B, Galicier L, et al. Rituximab, fludarabine, and alkylating agents in peripheral neuropathies related to IgM monoclonal antibody against myelin associated glycoprotein: A retrospective study of 15 patients. Proceedings of the 6th International Workshop on Waldenstrom's Macroglobulinemia, Venice, Italy 2010; p 122.
42. Ly KI, Fintelmann F, Forghani R, et al. The Bing-Neel Syndrome: Clinical observations on nine new cases and the literature. Proceedings of the 6th International Workshop on Waldenstrom's Macroglobulinemia, Venice, Italy 2010; p 133.
43. Merlini G, Palladini G. Diagnosis and therapy of amyloidosis. Proceedings of the 6th International Workshop on Waldenstrom's Macroglobulinemia, Venice, Italy 2010; p 124.
44. Gertz M. Treatment options for amyloid related disease in Waldenstrom Macroglobuinemia. Proceedings of the 6th International Workshop on Waldenstrom's Macroglobulinemia, Venice, Italy 2010; p 126.
45. Fermand JP. Renal manifestations of Waldenstrom's Macroglobulinemia. Proceedings of the 6th International Workshop on Waldenstrom's Macroglobulinemia, Venice, Italy 2010; p 127.
46. Stone MJ. Pathogenesis and morbidity of autoantibody syndromes in Waldenstrom's Macroglobulinemia. Proceedings of the 6th International Workshop on Waldenstrom's Macroglobulinemia, Venice, Italy 2010; p 129.
47. Bogen S. Identification of antigenic determinants in Waldenstrom's Macroglobulinemia. Proceedings of the 6th International Workshop on Waldenstrom's Macroglobulinemia, Venice, Italy 2010; p 51.
48. Dammacco F, Sansonno D. HCV-positive Macroglobulinemia. Proceedings of the 6th International Workshop on Waldenstrom's Macroglobulinemia, Venice, Italy 2010; p 131.
49. Morel P, Duhamel A, Gobbi P, et al. International prognostic scoring system for Waldenstrom Macroglobulinemia. Blood 2009; 113:4163-70
50. Morel P. Can WM ISS be used to make treatment decisions? Proceedings of the 6th International Workshop on Waldenstrom's Macroglobulinemia, Venice, Italy 2010; p 64.
51. Kastritis E. Prognostication of the high risk Waldenstrom's Macroglobulinemia patient. Proceedings of the 6th International Workshop on Waldenstrom's Macroglobulinemia, Venice, Italy 2010; p 66.
52. Owen, de Tute R, Rawstron AC. Response assessment in Waldenstrom's Macroglobulinemia. Proceedings of the 6th International Workshop on Waldenstrom's Macroglobulinemia, Venice, Italy 2010; p 86.